Anupam Rasayan India Limited — PPTs, 14-08-2026: Investor Presentation

Anupam Rasayan (ANURAS) kicked off FY27 strongly.

**Business Performance:** Consolidated revenue jumped 36% YoY to ₹667.5 Cr, driven by new products and healthy demand across segments. Consolidated EBITDA grew 35% YoY to ₹174.9 Cr, with PAT up 6% YoY to ₹51.2 Cr. EPS stood at ₹3.40. Growth was strong in Pharma and Performance Materials.

**Growth Drivers:** The company is building a globally integrated specialty chemicals and CDMO platform. Acquisitions of Jayhawk Fine Chemicals and the ongoing Bliss GVS Pharma deal are key to strengthening its CDMO and pharmaceutical capabilities and expanding into high-value segments. Backward integration with Tanfac Industries further strengthens the supply chain.

**Recent Developments:** ANURAS added 3 new products in Q1FY27, including commercializing Ethyl Trifluoroacetate (ETFA) using flow chemistry – a world-first. A Letter of Intent with BASQUEVOLT, S.A. offers a potential $300 million revenue opportunity over 10 years, starting FY27.

**Management Outlook:** Management is confident about future growth, citing a robust product pipeline, expanding opportunities in Performance Materials and Pharmaceuticals, deeper customer engagement, and ongoing investments in technology and innovation for sustainable value creation.